Deliver Your News to the World

Southwestern Medicalís Labguard(TM) Test to Improve Accuracy of Prostate Screening


WEBWIRE

Southwestern Medical Solutions, Inc. (Other OTC:SWNM.PK - News) is pleased to announce that it intends to introduce a version of the Labguard(TM) system to facilitate a simple urine test that could be used as an easy cross-check to the traditional PSA (prostate-specific antigen) test to increase the accuracy of prostate screening.

The Common Screening Test For Prostate Cancer Is Often Inaccurate

The most common screening test for prostate cancer is often inaccurate, leading to thousands of unnecessary biopsies per year. A scientist at Childrenís Hospital in Boston says he has found a marker in urine that was elevated in all men with untreated or aggressive forms of prostate disease. Men middle-aged and older routinely get blood tests for prostate-specific antigen, or íPSAí to screen for prostate cancer. PSA testing does have shortcomings, however, and many men with elevated PSAs donít have clinically significant prostate cancer and may undergo unnecessary treatments, which can cause infertility, incontinence, and impotence.

Southwestern Medical Will Improve Upon PSA Screening

Southwestern Medicalís Labguard(TM) system will facilitate the use of this new screening modality to allow a more effective, less invasive, and less costly solution. In a study conducted by Dr. Bruce Zetter from Childrenís Hospital Boston, it was shown that thymosin B15 levels were elevated in men with aggressive or untreated prostate cancer, but normal or near-normal levels in healthy men and/or men with other, non-malignant genitourinary diseases. It is proposed that a diagnostic test using the Labguard(TM) system will enable clinicians to routinely determine elevated levels of thymosin B15. SWNM researchers are proceeding to construct the prototype for this version of Labguard(TM) that will then undergo testing prior to a market launch.

Poised For Launch Into Enormous Healthcare Markets

Currently involved in clinical investigative studies for its patent-protected Labguard(TM) systems, Southwestern Medical Solutions continues to develop exciting advancements in products for the healthcare community. With the exclusive rights to produce and distribute the patented Protect-A-Pal(TM) safe syringe systems, and its potential entrance into the Hydrotherapy market, as well as disposable surgical devices, SWNM is poised to gain a strong market presence and build a healthy portfolio of high demand products.

The statements made in this press release, which are not historical facts, contain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of the specific items described in the release, and the companyís operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the companyís dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.



WebWireID2453





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.